Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | XDH | P47989 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383936 | 1.00 | CES2 (0.59) | CES2CES1CA1CA2CA12 | |
| SCHEMBL14012582 | 1.00 | CES2 (0.59) | CES2CES1CA1CA2CA12 | |
| SCHEMBL27558516 | 0.88 | ERN1 (0.49) | CES2CES1CA1CA2CA12 | |
| SCHEMBL4652494 | 0.85 | ERN1 (0.64) | CES2CES1CA1CA2CA12 | |
| SCHEMBL2456384 | 0.84 | CA1 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1401556 | 0.84 | KDM4E (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL851097 | 0.84 | CA1 (0.69) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1495863 | 0.84 | HDAC1 (0.62) | CA1CA2CA12CA7CA9 | |
| SCHEMBL854583 | 0.84 | NOTUM (0.54) | CA1CA2CA12CA7CA9 | |
| SCHEMBL523320 | 0.84 | KDM4E (0.62) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115306376-A | Oil-gas well fracturing monitoring reagent, method and application thereof | 中国石油天然气股份有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-114865080-A | Lithium ion battery electrolyte and lithium ion battery | 香河昆仑新能源材料股份有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-122070277-A | Androgen receptor PROTAC | 葛兰素史密斯克莱知识产权发展有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-116082311-B | Phthalazinone compound, preparation method and medical application thereof | 上海济煜医药科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119325476-A | Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-118696036-A | PARP1 inhibitors | 突触活化疗法股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118525011-A | Morpholinyl quinazoline compound, preparation method and application thereof | 上海璎黎药业有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-111278809-B | Bicyclic sulfones and sulfoxides, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-115594666-B | Synthesis and application of phosphatase degradation agent | 海创药业股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-114891003-B | Novel dihydropyrimidine compound, intermediate or salt, and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-112876482-B | Polysubstituted heterocyclic derivative, preparation method and medical application thereof | 中国药科大学 | 2023-07-28 | — | — | CN | disclosed |
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ITEOS BELGIUM S A (BE) | 2023-03-30 | — | — | US | disclosed |
| CN-115594666-A | Synthesis and application of phosphatase degrading agent | 海创药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115306376-A | Oil-gas well fracturing monitoring reagent, method and application thereof | 中国石油天然气股份有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-108473464-B | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-114891003-A | Novel dihydropyrimidine compounds, intermediates or salts, and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114865080-A | Lithium ion battery electrolyte and lithium ion battery | 香河昆仑新能源材料股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114729044-A | Muscarinic acetylcholine M1Receptor antagonists | 帕珀莱恩医疗公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114671875-A | Novel dihydropyrimidine compound, isomer or salt, and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-114656472-A | Pyrazolopyrimidine compound, isomer or salt, and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2022-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA1 | CES2 1584/4885CES1 2049/4885CA1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.